A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.

Pfizer

Overview

A 6-week double-blind study to evaluate the safety and efficacy of Quillichew extended release chewable tablets in 4-5 year old children with attention deficit hyperactivity disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity Disorder

Interventions

methylphenidate HCl ERCTDRUG

methylphenidate HCl ERCT

PlaceboDRUG

Placebo to Match Quillichew ERCT

Eligibility

Sex: ALLMin age: 4 YearsMax age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female child 4-5 years of age at baseline. 2. Signed and dated informed consent document. 3. Meets DSM-V criteria for ADHD based on the K-SADS-PL. 4. ADHD RS-IV Preschool Home Version score at Screening and Baseline \>/= 90th percentile for gender and age in \>/=1 of the following: hyperactive-impulsive subscale, inattentive subscale, or total score. 5. Peabody Picture Vocabulary Test 4 (PPVT4)Standard Score \>/=70. 6. Child Global Assessment Scale (CGAS) score \</= 55. Exclusion Criteria: 1. Treated with atomoxetine within 30 days prior to the Baseline. 2. Received any investigational products or devices within 30 days prior to the Baseline visit. 3. History of stimulant nonresponse, intolerability or hypersensitivity to any dose of Quillichew ERCT or other stimulant. 4. An intelligence quotient (IQ) \<70. 5. History of acute or chronic medical or psychiatric condition or cardiac or laboratory abnormality. 6. Less than 5th percentile for height or weight at Screening. 7. History of recent clinically significant self-harming behaviors.

Outcomes

Primary Outcomes

Safety-incidence of treatment emergent adverse events

incidence of treatment emergent adverse events

Time frame: 6 months

Attention Deficit Hyperactivity Rating Scale - IV (ADHD RS-IV) Preschool-Home Version

Change from Baseline to end of double-blind treatment in the total score of the Attention Deficit Hyperactivity Rating Scale - IV (ADHD RS-IV) Preschool-Home Version

Time frame: 6 weeks

Secondary Outcomes

incidence of adverse events

Time frame: 6 weeks

Clinical Global Impression of Improvement (CGI-I) Scale Score

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Clinician responded to a question: "Compared to your subject's condition at the beginning of treatment, how much has your subject changed?". Improvement was compared to baseline and was defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.

Time frame: weeks 1-6

Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18)

CBCL was standardized for children ages 4 to 18 years and measured child internalizing and externalizing behaviors and total problems. The 4-18 years' checklist contains 140 questions and responses were recorded on a Likert scale: 0 = Not True, 1 = Somewhat or Sometimes True, 2 = Very True or Often True. The range of possible values was 0-280 (0=good to 280=worst).

Time frame: Weeks 1-6

Children's Global Assessment Scale (CGAS)

CGAS: clinician-rated global assessment item for children based on symptoms and social functioning in home, school, and community settings. Scores on this single item range from 1 (most impaired) to 100 (healthiest); higher levels indicate greater health, with descriptive anchors for every 10-point interval. Scores above 70 on this scale are considered within the "normal" range; lower score indicates need for increased supervision.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.